Symbion Capital
Symbion is a prominent entrepreneurial hub in Denmark, dedicated to fostering the growth of startups and small businesses. Established in 1984, it provides a supportive environment where entrepreneurs can network, collaborate, and develop their ventures. Symbion operates four business centers in Copenhagen, offering office spaces, workplaces, and laboratories tailored for knowledge-intensive industries, including IT, Cleantech, and Life Sciences. The organization boasts a network of over 250 entrepreneurs and small companies, emphasizing high ambitions in becoming Denmark's center for entrepreneurship. Additionally, Symbion Capital serves as its investment arm, focusing on pre-seed, startup, and early-stage companies by providing mentorship, office space, and funding through its venture capital fund.
Accelerace, established in 2008 and located in Copenhagen, Denmark, is recognized as one of the top seed accelerators globally. The organization has identified, trained, and invested in over 700 high-potential startups and growth companies, with 88% of these ventures remaining active in the market. As a partner in the Scale-Up Denmark initiative, Accelerace focuses on scaling startups across various sectors, including foodtech, edtech, cleantech, fintech, and digital health, leveraging the expertise of experienced entrepreneurs and a comprehensive mentor network. The firm has invested more than 38.8 million USD into promising startups and has formed partnerships with notable organizations such as the Novo Nordisk Foundation and Bang & Olufsen. Accelerace also facilitates the Nordic Mentor Network for Entrepreneurship, aimed at supporting life science startups. The firm is particularly interested in emerging trends related to sustainability, personalized nutrition, and functional foods, recognizing their potential impact on health and consumer behavior.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.